Ventyx Biosciences Inc (VTYX)
4.74
-0.24
(-4.82%)
USD |
NASDAQ |
May 17, 16:00
4.74
0.00 (0.00%)
After-Hours: 20:00
Ventyx Biosciences Cash from Operations (Quarterly): -47.62M for March 31, 2024
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | -47.62M |
| December 31, 2023 | -51.66M |
| September 30, 2023 | -34.66M |
| June 30, 2023 | -49.28M |
| March 31, 2023 | -30.92M |
| December 31, 2022 | -47.26M |
| September 30, 2022 | -23.99M |
| Date | Value |
|---|---|
| June 30, 2022 | -14.79M |
| March 31, 2022 | -12.73M |
| December 31, 2021 | -14.69M |
| September 30, 2021 | -11.04M |
| June 30, 2021 | -9.903M |
| March 31, 2021 | -3.019M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (Quarterly) Range, Past 5 Years
-51.66M
Minimum
Dec 2023
-3.019M
Maximum
Mar 2021
-27.04M
Average
-23.99M
Median
Sep 2022
Cash from Operations (Quarterly) Benchmarks
| Anavex Life Sciences Corp | -11.66M |
| CERo Therapeutics Holdings Inc | -- |
| Avinger Inc | -3.389M |
| Checkpoint Therapeutics Inc | -6.474M |
| RAPT Therapeutics Inc | -27.08M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | 41.76M |
| Cash from Financing (Quarterly) | 96.18M |
| Free Cash Flow | -183.86M |
| Free Cash Flow Per Share (Quarterly) | -0.7731 |
| Free Cash Flow Yield | -65.09% |